Category Archives: Transhuman News

Image on Unsplash

The following post was written and/or published as a collaboration between Benzingas in-house sponsored content team and a financial partner of Benzinga.

The global market for over-the-counter (OTC) and prescription treatments that address age-related diseases and longevity is projected to more than quadruple in size over the next 5 years, growing from $110 billion today to more than $600 billion by 2025. This massive market is currently wide open as no Food and Drug Administration (FDA)-approved treatments targeting the underlying causes of aging exist yet, and many developers in the space are still focused on treatments and products that only alleviate the symptoms.

That could soon change with MYMD-1, the leading drug candidate from the clinical stage pharmaceutical company MyMD Pharmaceuticals Inc. (NASDAQ: MYMD). Phase 2 clinical trials for MYMD-1 begin this year following previous studies that confirmed its ability to regulate the immune system and curb inflammation.

The Anti-Aging Market Landscape

While the average human lifespan continues to grow increasing from 66.8 years in 2000 to 73.4 years in 2019 the quality of that longer life is not necessarily growing with it. In the United States alone, approximately 80% of adults 65 and older suffer from at least 1 chronic condition. More than 63% have 2 or more.

Jeff Bezos, the billionaire CEO of Amazon.com Inc. (NASDAQ: AMZN) and Peter Thiel, co-founder of PayPal Holdings Inc. (NASDAQ: PYPL), for example, both invested in anti-aging drug development.

The Link Between Inflammation and Aging

While a few companies are working on treatments for aging, their approaches vary widely, from targeting cellular senescence to using stem cells to regenerate healthy tissue. Some of the most promising research, however, lies in tumor necrosis factor alpha (TNF-) inhibitors which target inflammation.

Among common age-related diseases, the leading cause of death across the board was the damage caused by the chronic inflammation associated with all of them. Inflammation is responsible for a significant proportion of all deaths.

Story continues

Moreover, patients with chronic inflammation are at a higher risk of developing these debilitating diseases. Research suggests that as much as 15% of cancer diagnoses are linked to chronic inflammation. It also puts patients at a higher risk for developing cardiovascular disease, asthma and even neurodegenerative diseases like Alzheimers.

Proinflammatory cytokines TNF-, IL-6, IL-17 and others that the immune system produces trigger an inflammatory response that helps resist the disease. The acute inflammatory response is sort of like a state of emergency response.

Increased blood flow to the site of the infection causes swelling that helps block the invading substance from the rest of the body while dead or damaged tissue is eaten to stave off the spread of infection, a process that can cause pain.

While the pain, fatigue and general feeling of illness associated with this inflammatory response are uncomfortable, theyre important emergency protocols for fighting off disease. Once that disease is defeated, the immune system stops producing TNF- cytokines and returns the body to a normal state.

When youre suffering from a chronic condition, though, that fight is never really over. This can lead to the chronic presence of high levels of TNF- cytokines. What should be a temporary response becomes a chronic condition and prolonged inflammation can lead to organ damage as well as the development of chronic diseases.

How MyMD-1 Could Become the Leading Treatment in the Anti-Aging Market

MyMD-1 is a TNF-, IL-6 and IL-17 inhibitor that helps regulate this inflammatory response. While other similar drugs exist on the market, they come with adverse side effects including neurotoxicity, drug-induced lupus and life-threatening infections.

MyMD-1 is a TNF- inhibitor that helps regulate this inflammatory response. While other TNF inhibitors exist on the market, they come with adverse side effects including neurotoxicity, drug-induced lupus and life-threatening infections.

The current options are also nonselective, meaning they target all TNF cytokines rather than specifically going after TNF- the one most strongly linked to the chronic inflammatory conditions. This nonselective process can significantly impair patients immune systems, reducing their ability to fight off infections.

Available only as an injection, they also can be difficult and unpleasant to administer on your own.

MyMD-1 was formulated to address all 3 of these problems with current TNF inhibitors. The orally administered pill specifically targets TNF- with the aim of helping regulate the immune response without suppressing it to dangerously low levels. Preliminary clinical results show that MyMD-1 demonstrates anti-proliferative effects, which can inhibit cell growth.

As the company launches more Phase 2 trials this year, expect to see new data as early as the 1st quarter of 2022, putting the innovative TNF inhibitor a step closer to becoming the worlds 1st FDA-approved treatment for aging.

The preceding post was written and/or published as a collaboration between Benzingas in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

See more from Benzinga

2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

See the article here:
A First-of-its-Kind Drug Candidate Targeting the Root Causes of Aging Could Soon Dominate Estimated $600 Billion Aging Market - Yahoo Finance

Oil pulling is easy to do, inexpensive, and non-time-consuming.  |  Photo Credit: iStock Images

It is well-known thatoral health serves as a gateway to general health. This implies that oral health significantly impacts the general health and wellbeing of an individual.

The Express.co.uk cites a study published in the National Library of Health that analysed claims that the ancient Indian (Ayurvedic) practice of oil pulling helps reduce diseases and potentially extends longevity. Oil pulling is believed to cure more than thirty systemic diseases when practised regularly and as directed, began the study. It continued: Oil pulling in addition to offering several oral health benefits has also beneficial effects on overall health. The researchers examined claims that

The findings:

Earlier researches on oil pulling therapy:

According to a research paper published in the International Journal of Health Sciences (IJHS), periodontal diseases (such as gingivitis and periodontitis), and dental caries are the most common forms of oral diseases found to be significantly present in higher numbers in diabetic patients and those with heart diseases, as compared to the healthy population.

In fact, various studies have identified the periodontal disease as a risk factor for the etiology of coronary heart disease. But the danger of overusing chemical-based medicine persists and therefore to bombard the mouth cavity with erosive mouthwashes, dental treatments, corrosive kinds of toothpaste, or toothbrushes IS NOT THE ANSWER.

The above-mentioned paper that involved researchers from Canada, Saudi Arabia, Pakistan etc mention that Chlorhexidine mouthwashes are used as an adjunct to the clinical management of caries and periodontal diseases and apart from an unpleasant taste, it is their unwanted effects (staining) that are a cause for concern. In addition, the stannous within this oral rinse is associated with extrinsic staining of teeth, while the zinc and stannous salts have organoleptic properties, limiting its use to only concentrations. Using oil pulling techniques has not been associated with any such side effects, concludes the paper.

All that you must know about Oil Pulling Therapy:

This medical research paper cites that the process of oil swishing is believed to cure or control 30 different types of systemic diseases including headaches, migraines, and chronic diseases such as asthma and diabetes mellitus.Scientific evidence suggests that oil pulling therapy may reduce the total oral bacterial count and reduce plaque and gingival scores.

How to do Oil Pulling?

Several celebrities swear by the benefits of Oil Pulling. Anushka Sharma (the better half of cricketer Virat Kohli) is one of them.Jacqueline Fernandez, Shilpa Shetty and Gwyneth Paltrow are some of the others.

Diseases that go away or reduce due to oil pulling:

Several ailments are banished due to the practice of oil pulling taken up over a longer period, reported the IJHS study.

The IJHS research paper states that as per Ayurveda,this ancient Indian (Ayurvedic) technique can be used for the prevention and treatment of more than 30 different diseases, which vary from headaches, migraines, thrombosis, and eczema; to fatal diseases such as diabetes and asthma.

Disclaimer: Tips and suggestions mentioned in the article are for general information purpose only and should not be construed as professional medical advice. Always consult your doctor or a dietician before starting any fitness programme or making any changes to your diet.

Read more:
Cut the risk of heart attacks, diabetes and cancers and boost longevity: Take up this short, easy, inexpensive ancient Indian practice once daily -...

An new research suggests that ingesting less, frequently improves mouse nutrition and longevity further than merely consuming little.

Investigators studied mice on various meals and discovered that animals supplied less carbohydrates in a daily dose supper survived lengthier than mice fed same calorie count dispersed once a day.

The experiment, released in Nature Metabolism, found that mice that ate once a day better metabolic activity.

(Photo : Photo credit: YOSHIKAZU TSUNO/AFP via Getty Images)Mice peer out from a loaf of bread which they hollow out and use the crust to live in, during an attraction for New Year visitors at the Inokashira Park Zoo in suburban Tokyo 06 January 2008, on the last day of Japan's largest holiday. This year is the Year of the Rat, according to the Chinese zodiac.

Per the report's primary investigator, Dudley Lamming of the University of Wisconsin, scientists have known for almost a generation that carbohydrate restriction enhances rat longevity.

Nevertheless, earlier research on mice and dietary changes featured accidental dieting, with animals generally fed once per day.

Lamming's team proceeded to investigate if the time of meals played a factor and observed that it wasn't only the amount of meal that resonated.

"Rather, nutrition dietary habits guarantee that mice fast for majority of the day and the mandated calorie restriction is important for the advantages of calorie restriction on fitness and wellbeing."

Lamming's crew fed rats varied foods, with a controlling sample eating anything they wanted.

2 additional subgroups had their calorie reduced by 30%, with one getting low-calorie meal all day and alternative consuming a 30% lesser portion of conventional meal in a one mealtime after a 21hours fast.

According to the findings, mice on a nutrition regimen with 21 hours without meal survived roughly a half-year better than rats which consumed as much as they pleased every day.

A final group of mice was conditioned to consume the same portion size as the reference sample but during a three-hour period following a long continuous fast.

Like the first batch, the last group who dieted with lowering calorie consumption exhibited so many healthcare advantages.

While mice on a reduced meal who ate through the day,showed zerosignificant benets including as enhanced blood glucose management, increased vigor in old age, or a longevity.

Also read: German Scientists Develop a New Breathing Technique for Frogs

Intermittent fasting regimens are prominent amongst superstars ranging from Hugh Jackman to Kourtney Kardashian.

However, Lamming notes that, although brief clinical experiments appear to indicate that confining dietary consumption to a 4 to 8 hours perioda day "does have positive effects," the long-term implications are uncertain.

In response to the results, Stephen O'Rahilly, Chief of the MRC Metabolism Infections Institute at the University of Cambridge, stated that they might be difficult to extrapolate to mankind due to the vast disparities in the rates where the 2 species absorb nutrition.

"An equivalent humanity research should require individuals to consume all of the carbohydrates they require a week in a one day and then hunger for next six days," he explained.

"Because mice survive approximately 2 years and human beings currently survivearound 80 years. Humans may need to carry out this study for further than 50 years to see if such a drastic shift in our dietary habits truly enhanced life span," he concluded.

Another potential implication for our species, according to Lamming, is that those who previously reduced their daily calories by 20% to 30% might want to contemplate reducing the time frame for consuming foods.

"Should our discoveries extend to humans," Lamming says, "they could be sacrificing a few of the perks of dietary changes by spacing out their food each day."

Also read: Living Fossil: Alligator Gar Existing 100 Million Years Ago Captured by Kansas Fisherman

2021 NatureWorldNews.com All rights reserved. Do not reproduce without permission.

Original post:
New Experiment in Mice Reveals Fasting May Offer More Health Benefits Than Losing Weight - Nature World News

A study in rats found that reducing calories and eating them in the same diet was the best way to live longer and stay healthy.

Researchers at the University of Wisconsin have found that although eating a low-calorie diet is good for health, fasting and dieting are better.

The study found that rodents in the fasting group reduced their calorie intake by 30 percent and lived eight months longer than those who lived on low calories.

The combination of fasting and diet improved insulin sensitivity and republished the metabolism to focus on using body fat as an energy source.

Leading researcher Professor Dudley Laming said the focus should be on foods or medications that focus on fasting, rather than calorie control, if it is to be a major motivator of health.

However, one expert pointed out that the results of the study were not applicable to humans due to the very large biological differences between humans and mice.

The researchers designed four different diets for mice, which were mainly followed by males.

One group ate whenever they wanted, while the second group ate full amount, but in the short term, provided a long daily fast without reducing calories.

The other two groups were given about 30% fewer calories, and one of them was able to consume all the calories in one serving so that her fast was longer every day, while the other group ate the same amount, but distributed in one day.

This study, published in Natural Metabolism, found that rats ate their daily calories for a short period of time and then fasted longer than the rats they ate when they wanted to.

Furthermore, rats that were fasting enjoyed the same benefits of calorie control with fasting, without reducing calories.

The liver of fasting mice also showed characteristics of healthy metabolism.

Meanwhile, mice that ate fewer calories without fasting showed some improvement in their blood sugar control, but they died about eight months younger than mice that ate less and fasted.

Professor Laming said that because rats alone reduced calories, overall health was poor and life expectancy was reduced.

If fasting is the main motivator of health, we should consider fasting-responding medications or dietary interventions rather than low-calorie medications, he added.

Professor Sir Stephen OReilly, director of the Department of Metabolism at the Center for Cancer Research at the University of Cambridge, said the findings were interesting but very difficult to differentiate between humans.

Considering the differences in rat speed and human body function, a similar study in humans stated that humans should eat all the calories they need for a week in one day and go hungry for the next 6 days.

Since rats live for about two years and now we live an average of 80 years, we will have to conduct more than 50 years of research to see if this massive change in our eating habits can actually help prolong human life, Stephen added.

He noted that such a test was not feasible.

Source: Daily Mail

Continue reading here:
The study reveals what the 'key' to longevity and agility is - Dubai Week

Although the length of human life is limited, recent studies show a promising route to achieve a healthy late life

The increasing ageing population represents a remarked worldwide socioeconomic challenge. Pharmacological interventions of ageing appear to be an effective approach to slow down or even reverse ageing, which extends health span and delays the onset of age-related diseases including cancer, cardiovascular disease and neurodegeneration 1. Recently, several encouraging research results suggest that there are at least two reasonable approaches to might grant us to live longer and healthier.

Drug repurposing

Considering that new drugs are difficult, expensive and very time consuming to develop, it is sensible to repurpose old drugs to treat other diseases than originally targeted. In fact, a considerable portion of anti-ageing drug candidates is known. These drugs target signal pathways that have been shown to be key regulators of ageing. Repurposing these drugs is de-risk because of potentially lower cost and shorter development time.

For example, the FDA-approved mTOR-targeted drug rapamycin and its analogs (rapalogs) is one of the top anti-ageing candidates. It has been shown that rapamycin can improve health and extend lifespan in diverse animal models. It targets specifically to mTOR which considered is dysregulated at old age, resulting in morbidity increase in the elderly. Recent clinical trials studying health in elderly found that a low dose of rapalog enhances immune responses to influenza vaccination compared to control subjects, indicating that rapalog boosts immune system to attenuate immunosenescence and improve health at the old age 2, 3.

Remarkably, a recent study highlights that the anti-age effect of rapamycin treatment is caused by epigenetic changes in intestines in fruit flies and mice 4. It raises a big interesting question whether this will be a new promising anti-ageing route, because the epigenetic changes, one of the hallmarks of ageing 5, can be reprogrammed to recover youthful epigenetic information, which not only slows down but even reverses ageing in mice 6. To decipher the communication code between rapamycin and epigenetic changes and how they can work together to extend healthy longevity is of greatest interest and importance in the ageing research field.

Drug combination

Drug combination (polypill) is another encouraging approach, especially considering the complex ageing process, and most of the already existing drugs only target very specific cellular processes involved in ageing. To combine several drugs, which target different cellular pathways in the ageing cell, could have beneficial effects on longevity and this approach has great potential. This was clearly demonstrated in a study showing that giving fruit flies doses of rapamycin, lithium and trametinib in combination has additive outcome on lifespan extension. While each drug individually extends the lifespan of flies by an average of 11 percent, combining all three drugs extended lifespan by about 30 percent 7. Another study on microscopic worm (C. elegans) shows that an anti-ageing drug cocktail not only increases healthy lifespan but also delays the rate of ageing in the worms 8. These proof-of-principle studies suggest that drug combination is potentially important in combating ageing, although further tests in other animal models have to be evaluated before they can be considered in clinical trials.

In short, there is a long way to go before we will be able to imply these effective treatments to slow down ageing in humans, and the possible side effects of drug treatments have to be carefully considered, but the research results look very promising for future treatment of ageing-related health problems.

Dr Yu-Xuan Lu is an ageing scientist from Max Planck Institute for Biology of Ageing, Germany (Panellist at International Biology Conference, Darwin hosted byBioriidl- from Dec 2-5, 2021)

Read more from the original source:
Combating ageing with pharmacological interventions - BSA bureau

In 2012, the IMF published the Global Financial Stability Report (GFSR), and in chapter 4, it warned about the financial impact of longevity risk. The IMF stated in the document: The financial implications of people living longer than expected (so-called longevity risk) are very large. The institution coldly pointed out that delaying the retirement age allowed the period of accumulation of pension resources to be prolonged and then, with late retirement, the period of use of these resources is shortened, given the natural time of human existence.

By Miguel Julio Rodrguez Villafae

However, the report did not analyse the negative implications for individuals and peoples of demanding the payment of illegitimate, odious, illegitimate and usurious eternal foreign debts imposed by the worlds financial power. And by no means did the IMF say anything about the fact that, in 2017, the government of Mauricio Macri contracted a 100-year debt, with an interest rate of 8.25 per cent per annum, which was one of the most profitable financial operations for the big international investment funds, which conditioned the future of more than six generations of Argentinians.

However, it is always made to appear that the culprits of the budget imbalances are the so-called passive class. And they are presented as a charge on society, particularly if they live too long. All this without any critical, legal or moral judgement on the subject.

At the same time, the medias handling of the issue does not touch on the foreign debt payments at all, but rather sugarcoats them, without forcing a freeze on payments and an audit to determine whether they are legally due for payment.

But the seriousness also lies, among other great internal discriminations against retirees and pensioners, and nobody refers to it, with respect to the debts owed to them, which are undisputed and legitimate. It is worth mentioning that the current Law 24.463 of the Social Security Judicial Procedure, of 1995, unjustly determines, in article 21, that, in the case of social security lawsuits, in all cases the costs will be in their order. In other words, even though retirees and pensioners have won a lawsuit against the National Social Security Administration (ANSeS), they still have to pay their costs and lawyers fees.

The aforementioned goes against the provisions of the National Constitution (arts. 14 bis, 16, 17, 18 and 28) and the Inter-American Convention on the Protection of the Human Rights of Older Persons, signed by Argentina and ratified by Law 27.360 of 2017. The Convention provides, among other statements on the subject, that States Parties shall adopt and strengthen all legislative, administrative, judicial, budgetary and any other measures, including adequate access to justice in order to guarantee the elderly a differentiated and preferential treatment in all areas, (art. 4, para. c).

Article 21 of Law 24.463, which has been in force for more than 26 years, has still not been repealed and the National State has ratified it and has made and continues to make abusive use of it. This is because, as it does not have to pay the costs, it interposes all possible appeals to all court instances, in order to delay any judicial resolution, even when there is peaceful jurisprudence, contrary to the position taken by the ANSeS on the issue in question.

At the same time, the undue and cruel delay, to which the National State subjects the plaintiffs in order to have their rights recognised, in matters of food and vital content, not only damages their patrimony, but also attacks one of the scarce assets of the elderly, such as their time. Late recognition of their rights often prevents them from enjoying what is rightfully theirs.

Furthermore, the rule goes against the general principle of legal costs, which is determined by article 68 of the Code of Civil and Commercial Procedure of the Nation -Law 17.454-, which states: the losing party in the trial must pay all the costs of the opposing party, even if the latter has not requested it, with the judge only being able, exceptionally, to totally or partially exempt the losing litigant from this responsibility.

In December 2017, the new National Law 27.423 on Lawyers Fees in the federal justice system made progress on the issue and the National Congress determined, in art. 36, that in social security cases Costs shall be imposed in accordance with the provisions of the Civil and Commercial Procedure Code of the Nation, that is, in accordance with the aforementioned art. 68. Immediately afterwards, President Mauricio Macri issued the Decree of Necessity and Urgency 157, in February 2018, by which he repealed article 36. The government understood, evidently, that the payment of fees that should be paid to the State responsible for the delay, was against the economic objectives set by the IMF.

The issue is unacceptable, let us note that pension victims must always pay lawyers fees when they have to sue the defaulting State, while the Vulture Funds, in the settlement carried out by Mauricio Macri in April 2016, were paid their lawyers fees, even in cases that they lost, such as the seizure of the Libertad frigate in Ghana, in which Argentina won the court case.

In 2019, I proposed to the Specialised Commission of Human Rights of the Elderly of the Bar Association of Cordoba to make a big move, to repeal as soon as possible, the unjust and undue art. 21 of Law 24.463, for being unconstitutional and seriously affecting the rights of retirees and pensioners and to reinstate article 36 of National Law 27.423, which was repealed by DNU. Unfortunately, although the Commission endorsed the proposal, the Pension Law Chamber of the College and the College itself, even today, more than two years later, have not made any progress on it. Could it be that they are arguing that it is easier for lawyers to collect their fees from the pensioners money, when they are paid what is owed to them, than to execute the State that lost the trial?

We are all responsible for the tremendous injustice to our elders. We cannot look the other way on this issue.

(*) Constitutional lawyer and journalist and opinion columnist.

Read more here:
Argentina: IMF and injustices with retirees and pensioners - Pressenza, International Press Agency

Wealth is in the hands of first and second-generation families involved in Australian and Asian family offices with over 70% of family offices wanting to keep the fund alive for further than one generation.

According to a survey conducted by KPMG and high net worth family office network The Table Club (TTC), which examined more than 80 family offices in Australia, Hong Kong, New Zealand and Singapore, found wealth from family offices was concentrated around Sydney and Melbourne with over 70% of the 500 wealthiest TTC members (TTC 500) residing in these locations, averaging about $1 billion each.

But it was Western Australia who led the pack with an average of $2.5 billion, while also holding the fastest growth in wealth at +31%.

Growth and longevity were the two key themes of the survey with 66% aiming to grow capital compared to 21% wanting to preserve capital for future generations.

Over half were targeting returns of 6% to 10% over the next five years while 43% had made impact investments.

Robyn Langsford, lead partner family business at KPMG Australia, said the growth that family offices achieved during COVID-19 during periods of massive fiscal and monetary stimulus was a standout.

First and second generations continue to dominate family offices, Langsford said.

They are on the front foot - responding to the need for more formal governance structures and recognising the benefits of bringing in outside human capital to help manage growth and strategy. The key skill will be in their maintaining control and ownership through subsequent generations.

James Burkitt, TTC founder, said: Our aim was to learn more about the evolution of family offices in the region, and to understand how participants were managing macro challenges.

We also wanted to capture the granular detail across a sizeable sample of family offices to unveil secrets of success.

Over 60% of the TTC 500 primarily generated their wealth in the traditional asset classes of property, investment (which included operational businesses, private equity, credit and other asset classes), and financial services.

A further 105 members (21%) had an estimated wealth between $100 million to $200 million, with the majority of TTC 500 members having wealth between $200 million to $1 billion.

See the original post here:
Family offices focus on growth and longevity - Money Management

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (MyMD or the Company), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m. ET in Track 1. The conference is being held at the Wyndham Grand Jupiter at Harbourside Place in Jupiter, Florida.

MyMD Chief Scientific Officer Adam Kaplin, M.D., Ph.D. will discuss the multiple indications for each of MyMDs novel drug candidates, MYMD-1 and Supera-CBD. A webcast of the presentation will be available live and on demand for 90 days after the conference.

About MYMD-1MYMD-1s primary purpose is to slow the aging process and extend healthy lifespan, and it is also showing promise as a potential treatment for post- COVID-19 complications and as an anti-fibrotic and anti-prolific therapeutic. MYMD-1 has shown effectiveness in regulating the immune system by performing as a selective inhibitor of tumor necrosis factor-alpha (TNF-), a driver of chronic inflammation. Unlike other therapies, MYMD-1 has been shown to selectively block TNF- when it becomes overactivated in autoimmune diseases and cytokine storms, but not block it from doing its normal job of being a first responder to any routine type of moderate infection. MYMD-1s ease of oral dosing is another differentiator compared to currently available TNF- blockers, all of which require delivery by injection or infusion. No approved TNF inhibitor has ever been dosed orally. In addition, the drug is not immunosuppressive and has not been shown to cause the serious side effects common with traditional therapies that treat inflammation. MyMD expects to launch two Phase 2 trials during the current quarter for MYMD-1 one for delaying aging and prolonging healthy lifespan, and the other for post- COVID-19 depression and cytokine elevation.

About Supera-CBDSupera-CBD is MyMDs pre-clinical patented synthetic cannabidiol (CBD) derivative that is being developed as a pharmaceutical drug to address anxiety, pain, and neurodegeneration. Supera-CBD targets the cannabinoid receptor type 2 (CB2), a protein mainly expressed in the immune system and which is associated with the therapeutic effects of CBD, including its anxiolytic, anticonvulsant, antipsychotic, neuroprotective and anti-inflammatory properties. CB2 receptors do not create an intoxicating negative psychotropic reaction (e.g. a high). In contrast, CB1 is usually expressed in the brain and distributed throughout the central nervous system to deliver an intoxicating effect. A vast majority of CBD developers are pursuing compounds targeted to CB2 that have minimal CB1 affinity. MyMDs Supera-CBD, with low CB1 affinity and four-fold increased CB2 binding, is 8,000 times more potent a CB2 agonist (activator) than regular CBD. The Company believes that Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

About MyMD Pharmaceuticals, Inc.MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases and COVID-19- associated depression. The Companys second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit http://www.mymd.com.

Cautionary Statement Regarding Forward-Looking StatementsThis press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and none of MyMD nor its affiliates assume any duty to update forward-looking statements. Words such as "anticipate," "believe," "could," "estimate," "expect," "may," "plan," "will," "would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: the timing of, and MyMDs ability to, obtain and maintain regulatory approvals for clinical trials of MyMDs pharmaceutical candidates; the timing and results of MyMDs planned clinical trials for its pharmaceutical candidates; the amount of funds MyMD requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which MyMD operates; MyMDs ability to retain and attract senior management and other key employees; MyMDs ability to quickly and effectively respond to new technological developments; MyMDs ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on MyMDs proprietary rights; and the impact of the ongoing COVID-19 pandemic on MyMDs results of operations, business plan and the global economy. A discussion of these and other factors with respect to MyMD is set forth in the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, filed by MyMD on August 16, 2021. Forward-looking statements speak only as of the date they are made and MyMD disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Continue reading here:
MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth...